Summit Therapeutics, Inc. (SMMT)
13.73
-0.60
(-4.19%)
USD |
NASDAQ |
Aug 28, 16:00
13.73
0.00 (0.00%)
After-Hours: 20:00
Summit Therapeutics Free Cash Flow : -458.40M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -458.40M |
| March 31, 2026 | -387.48M |
| December 31, 2025 | -326.53M |
| September 30, 2025 | -274.73M |
| June 30, 2025 | -211.82M |
| March 31, 2025 | -174.20M |
| December 31, 2024 | -142.74M |
| September 30, 2024 | -113.54M |
| June 30, 2024 | -96.67M |
| March 31, 2024 | -93.69M |
| December 31, 2023 | -76.74M |
| September 30, 2023 | -54.52M |
| June 30, 2023 | -45.69M |
| March 31, 2023 | -34.01M |
| December 31, 2022 | -40.19M |
| September 30, 2022 | -52.18M |
| June 30, 2022 | -68.73M |
| March 31, 2022 | -70.09M |
| December 31, 2021 | -71.43M |
| September 30, 2021 | -72.37M |
| June 30, 2021 | -66.81M |
| March 31, 2021 | -61.93M |
| Date | Value |
|---|---|
| December 31, 2020 | -49.97M |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| January 31, 2020 | |
| October 31, 2019 | |
| July 31, 2019 | |
| April 30, 2019 | |
| January 31, 2019 | -34.52M |
| October 31, 2018 | -37.02M |
| July 31, 2018 | -45.77M |
| April 30, 2018 | -19.93M |
| January 31, 2018 | -20.42M |
| October 31, 2017 | -20.24M |
| July 31, 2017 | 29.75M |
| April 30, 2017 | 13.79M |
| January 31, 2017 | 14.97M |
| October 31, 2016 | 14.70M |
| July 31, 2016 | -28.00M |
| April 30, 2016 | -28.83M |
| January 31, 2016 | -25.57M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| NovelStem International Corp. | -0.2295M |
| Brainstorm Cell Therapeutics, Inc. | -4.057M |
| Kezar Life Sciences, Inc. | -42.03M |
| Protara Therapeutics, Inc. | -66.49M |
| Clene, Inc. | -16.00M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -140.55M |
| Cash from Investing (Quarterly) | 222.41M |
| Cash from Financing (Quarterly) | 230.57M |
| Free Cash Flow Per Share (Quarterly) | -0.1818 |
| Free Cash Flow to Equity (Quarterly) | -141.81M |
| Free Cash Flow to Firm (Quarterly) | -141.46M |
| Free Cash Flow Yield | -4.36% |